Ebola virus disease-related stigma among survivors declined in Liberia over an 18-month, post-outbreak period: An observational cohort study.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 07 2018
accepted: 23 01 2019
revised: 11 03 2019
pubmed: 28 2 2019
medline: 30 3 2019
entrez: 28 2 2019
Statut: epublish

Résumé

While qualitative assessments of Ebola virus disease (EVD)-related stigma have been undertaken among survivors and the general public, quantitative tools and assessment targeting survivors have been lacking. Beginning in June 2015, EVD survivors from seven Liberian counties, where most of the country's EVD cases occurred, were eligible to enroll in a longitudinal cohort. Seven stigma questions were adapted from the People Living with HIV Stigma Index and asked to EVD survivors over the age of 12 at initial visit (median 358 days post-EVD) and 18 months later. Primary outcome was a 7-item EVD-related stigma index. Explanatory variables included age, gender, educational level, pregnancy status, post-EVD hospitalization, referred to medical care and EVD source. Proportional odds logistic regression models and generalized linear mixed-effects models were used to assess stigma at initial visit and over time. The stigma questions were administered to 859 EVD survivors at initial visit and 741 (86%) survivors at follow-up. While 63% of survivors reported any stigma at initial visit, only 5% reported any stigma at follow-up. Over the 18-month period, there was a significant decrease in stigma among EVD survivors (Adjusted Odds Ratio [AOR], 0.02; 95% Confidence Interval [CI], 0.01-0.04). At initial visit, having primary, junior high or vocational education, and being referred to medical care was associated with higher odds of stigma (educational level: AOR, 1.82; 95%CI, 1.27-2.62; referred: AOR, 1.50; 95%CI, 1.16-1.94). Compared to ages of 20-29, those who had ages of 12-19 or 50+ experienced lower odds of stigma (12-19: AOR, 0.32; 95%CI, 0.21-0.48; 50+: AOR, 0.58 95%CI, 0.37-0.91). Our data suggest that EVD-related stigma was much lower more than a year after active Ebola transmission ended in Liberia. Among survivors who screened negative for stigma, additional probing may be considered based on age, education, and referral to care.

Sections du résumé

BACKGROUND
While qualitative assessments of Ebola virus disease (EVD)-related stigma have been undertaken among survivors and the general public, quantitative tools and assessment targeting survivors have been lacking.
METHODS AND FINDINGS
Beginning in June 2015, EVD survivors from seven Liberian counties, where most of the country's EVD cases occurred, were eligible to enroll in a longitudinal cohort. Seven stigma questions were adapted from the People Living with HIV Stigma Index and asked to EVD survivors over the age of 12 at initial visit (median 358 days post-EVD) and 18 months later. Primary outcome was a 7-item EVD-related stigma index. Explanatory variables included age, gender, educational level, pregnancy status, post-EVD hospitalization, referred to medical care and EVD source. Proportional odds logistic regression models and generalized linear mixed-effects models were used to assess stigma at initial visit and over time. The stigma questions were administered to 859 EVD survivors at initial visit and 741 (86%) survivors at follow-up. While 63% of survivors reported any stigma at initial visit, only 5% reported any stigma at follow-up. Over the 18-month period, there was a significant decrease in stigma among EVD survivors (Adjusted Odds Ratio [AOR], 0.02; 95% Confidence Interval [CI], 0.01-0.04). At initial visit, having primary, junior high or vocational education, and being referred to medical care was associated with higher odds of stigma (educational level: AOR, 1.82; 95%CI, 1.27-2.62; referred: AOR, 1.50; 95%CI, 1.16-1.94). Compared to ages of 20-29, those who had ages of 12-19 or 50+ experienced lower odds of stigma (12-19: AOR, 0.32; 95%CI, 0.21-0.48; 50+: AOR, 0.58 95%CI, 0.37-0.91).
CONCLUSIONS
Our data suggest that EVD-related stigma was much lower more than a year after active Ebola transmission ended in Liberia. Among survivors who screened negative for stigma, additional probing may be considered based on age, education, and referral to care.

Identifiants

pubmed: 30811388
doi: 10.1371/journal.pntd.0007185
pii: PNTD-D-18-01115
pmc: PMC6411197
doi:

Banques de données

figshare
['10.6084/m9.figshare.7670543']
ClinicalTrials.gov
['NCT02431923']

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007185

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI146268
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Dis. 1999 Feb;179 Suppl 1:S268-73
pubmed: 9988194
Am J Ophthalmol. 2017 Mar;175:114-121
pubmed: 27998698
Trop Med Int Health. 2002 Dec;7(12):1068-75
pubmed: 12460399
N Engl J Med. 2015 Jun 18;372(25):2467-9
pubmed: 26083224
Am J Law Med. 2016 May;42(2-3):223-255
pubmed: 29086642
BMJ Glob Health. 2016 Nov 18;1(3):e000108
pubmed: 28588963
PLoS Negl Trop Dis. 2016 Oct 18;10(10):e0005077
pubmed: 27755553
Lancet Infect Dis. 2016 Mar;16(3):331-8
pubmed: 26725449
Health Hum Rights. 2016 Jun;18(1):115-128
pubmed: 27781004
Sociol Health Illn. 2009 Apr;31(3):441-55
pubmed: 19366430
Soc Sci Med. 2008 Oct;67(8):1225-35
pubmed: 18599171
Clin Infect Dis. 2018 Jan 6;66(1):131-133
pubmed: 29020205
N Engl J Med. 2015 Aug 27;373(9):787-9
pubmed: 26222382
Front Public Health. 2016 Jul 04;4:142
pubmed: 27458576
Lancet Glob Health. 2017 Mar;5(3):e254-e256
pubmed: 28193386
Global Health. 2012 Jun 13;8:15
pubmed: 22695277
MMWR Morb Mortal Wkly Rep. 2014 Dec 19;63(50):1205-6
pubmed: 25522090
Clin Infect Dis. 2017 Feb 15;64(4):513-516
pubmed: 27940938
PLoS Negl Trop Dis. 2017 Sep 11;11(9):e0005907
pubmed: 28892520
PLoS Negl Trop Dis. 2017 Aug 24;11(8):e0005845
pubmed: 28837554
Infect Dis Poverty. 2017 May 10;6(1):71
pubmed: 28486978
Bull World Health Organ. 2016 Mar 1;94(3):210-4
pubmed: 26966332
Lancet Infect Dis. 2017 May;17(5):545-552
pubmed: 28094208
BMJ Glob Health. 2018 Mar 17;3(2):e000471
pubmed: 29607096
Lancet Infect Dis. 2017 Jun;17(6):571-573
pubmed: 28258816

Auteurs

J Daniel Kelly (JD)

Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.

Sheri D Weiser (SD)

Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America.

Barthalomew Wilson (B)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.

Joseph B Cooper (JB)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.

Meekie Glayweon (M)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.

Michael C Sneller (MC)

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America.

Clara Drew (C)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
Division of Biostatistics, University of Minnesota, Minneapolis, MN, United States of America.

Wayne T Steward (WT)

Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America.

Cavan Reilly (C)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
Division of Biostatistics, University of Minnesota, Minneapolis, MN, United States of America.

Kumblytee Johnson (K)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.

Mosoka P Fallah (MP)

U.S. Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
National Institute of Public Health, Ministry of Health, Monrovia, Liberia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH